COMPARE · Data as of August 28, 2026
BCH vs NWG
Verdict: Side-by-side breakdown using the Bull Rankings model. BCH scored 64.0, NWG scored 75.0 — NWG leads.
Compare another set
BCH
Banco de Chile
84.7Fin
$41.70 · $21.1B
fundamentals as of
Strength gap
8.3
BCH leads
NWG
NatWest Group plc
76.4Fin
$18.87 · $74.9B
At a glance · who leads each dimension, on the model's own rules
- CheapestNWG9.3x
- Fastest growthNWG+13.3%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
Fundamentals, head-to-head
BCH
NWG
-1.6%D+
Rev
+13.3%B+
15.8xC+
P/E
9.3xA-
21.6%A-
ROE
14.8%B
0.74A
P/B
1.42B+
5.3%A-
Yield
5.0%A-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
BCHBanco de Chile
Why now
Banks - Regional · market cap $21.1b. 11% off the 52-week high of $46.77. 12 sell-side analysts rate this a Hold with a mean 1-yr target of $39.88 (implying -4% upside).
Moat
Net margin 45% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.
Risk
Dividend payout 85% of earnings on a 5.3% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
NWGNatWest Group plc
Why now
Banks - Regional · market cap $74.9b. Trading near 52-week high of $19.42 — momentum setup, limited technical margin of safety. Revenue growing +13%, comfortably above the S&P median. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $21.54 (implying +14% upside).
Moat
Net margin 38% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $74.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.